

UVA Advanced Cardiac Valve Center



Advanced Care

UVA Advanced Cardiac Valve Center is one of only a few sites in the United States offering the full spectrum of options for repairing and replacing cardiac valves. We're at the forefront of innovation in heart valve disease.

Our multidisciplinary team of valve experts evaluates each individual case to determine the approach best suited to the patient. Our doctors also work closely with referring physicians to select the best course of treatment. UVA offers rapid access to nationally recognized leaders.

Conditions Treated

- Bicuspid or congenital anomaly
- Stenosis
- Regurgitation
- Endocarditis

Available Treatments

UVA Advanced Cardiac Valve Center offers the full complement of treatment options available for heart valve disease, including:

Transcatheter approach

- Percutaneous mitral valve repair (MitraClip®)
- Transcatheter aortic valve replacement (TAVR)
- Percutaneous pulmonary valve implantation

Surgical approach

- Aortic valve replacement
- Open heart surgery

- Minimally invasive valve surgical repair (mini valve) or replacement
- Hybrid approach consisting of staged initial percutaneous coronary interventions followed by valve surgery for patients with complex coronary and valve disease

Transcatheter Approach

TAVR

At the American College of Cardiology Annual Scientific Session, researchers reported that hospitals that perform a high volume of transcatheter aortic valve replacement (TAVR) procedures have better outcomes. This report is based on an observational study of more than 40,000 patients on the Transcatheter Valve Therapy (TVT) registry.

The UVA team has been performing TAVR since it was first introduced in 2009, as one of 26 U.S. sites selected to participate in the initial PARTNER trial. Since that time, UVA has completed nearly 400 TAVR procedures.

The study evaluated how many TAVR procedures were performed at nearly 400 U.S. hospitals and how often patients experienced death, vascular complications, bleeding or stroke following the procedure. The result: a statistically significant association between higher volume and reduced mortality.

MitraClip®

MitraClip is an effective treatment for patients with severe degenerative mitral regurgitation who are at prohibitive risk for open heart surgery.

UVA is among the first centers in the country to perform

MitraClip insertion to repair mitral regurgitation. UVA was a MitraClip clinical trial leader and our surgeons are recognized as leaders in performing device insertion.

Surgical Approach

UVA has a long and experienced 58 year history of open valve procedures. UVA performs 450 open and minimally invasive valve surgeries each year, with superior results. Patients with valve disease may be candidates for this minimally invasive valve replacement or repair.

A leader in the field, UVA Advanced Cardiac Valve Center serves as a training site for minimally invasive valve repair for surgeons across the country, in addition to patients with more complicated conditions. The mini valve approach offers the following benefits:

- Faster recovery
- Shorter hospital stay (as few as 3-4 days)
- Reduced risk of atrial fibrillation
- Lower risk of blood transfusion
- Less scarring

UVA is actively involved in research and development.

Research

UVA has an accomplished history of participation in valve studies and continues to push for safer approaches and ways to bring the latest technology to more patients. UVA Advanced Cardiac Valve Center is involved in high-profile clinical trials that directly impact the way we treat cardiovascular disease nationwide. UVA is one of eight accredited core members of the Cardiothoracic Surgical Trials Network (CTSN), sponsored by the National Institutes of Health/National Heart Lung and Blood Institute.

Clinical Trials

We invite referring providers to consider enrolling patients with heart valve disease in one of our clinical trials. Currently enrolling trials include:

Research Study for Adults Who Are Planning Mitral Valve Surgery and Who Have Tricuspid Valve Regurgitation (IRB 18704)

The purpose of this study is to determine whether repairing the tricuspid valve in patients with mild to moderate tricuspid regurgitation (TR) at the time of planned mitral valve surgery would improve the heart health of those who receive it compared to those who do not. Study involves having your planned mitral valve surgery with the possible repair of your tricuspid valve at the same time. All patients in the study will be

followed for a period of five years after surgery with follow-up echocardiograms to see how the heart is doing.

UVA Principal Investigator | Gorav Ailawadi, MD
Contact: J. Mike Cosner, RN, BSN
Phone: **434.243.0315**

Surgical Implantation of Transcatheter Valve in Native Mitral Annular Calcification (SITRAL Study)
(IRB 19773)

The purpose of this study is to establish safety and feasibility of the Edwards SAPIEN 3 valve in patients with mitral annular calcification (MAC) associated with mitral stenosis and/or mitral regurgitation who are at high risk for mitral valve surgery or deemed inoperable due to the extent of calcification. Patients will be followed clinically for one year after the mitral valve surgery with echocardiograms and cardiac CT scans to see how the valve and heart are functioning.

UVA Principal Investigator | Gorav Ailawadi, MD
Contact: Rachel Simon, RN, BSN, CCRC
Phone: **434.243.0315**

PARTNER 3 Trial: Aortic Valve-In-Valve (IRB 19733)

A prospective, single-arm, multicenter study to investigate the safety and effectiveness of the SAPIEN 3 transcatheter heart valve implantation in patients with a failing aortic bioprosthetic valve. After receiving the SAPIEN 3 valve, subjects will be followed clinically for 10 years with echocardiograms to see how the valve and heart are functioning.

UVA Principal Investigator | Gorav Ailawadi, MD
Contact: Rachel Simon, RN, BSN, CCRC
Phone: **434.243.0315**

Evaluation of Transcatheter Aortic Valve Replacement Compared to Surveillance for Patients With Asymptomatic Severe Aortic Stenosis (EARLY TAVR Trial) (IRB pending; trial expected to open mid-May.)

Patients who have asymptomatic severe aortic stenosis, and choose to participate in this trial, will be randomized 1:1 to receive TAVR with a SAPIEN 3 valve or to receive optimal clinical surveillance. Patients will be followed clinically for up to 10 years with interval echocardiograms to see how the heart valve and heart are functioning.

UVA Principal Investigator | Gorav Ailawadi, MD
Contact: Rachel Simon, RN, BSN, CCRC
Phone: **434.243.0315**

To refer a patient to UVA Advanced Cardiac Valve Center, call **434.200.8413**.